BackAcura Pharmaceuticals Overview

Acura Pharmaceuticals Other Current Liabilities

Track Acura Pharmaceuticals's other current liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$0.00

Peer average

Loading

Acura Pharmaceuticals Other Current Liabilities History

Loading

Acura Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Acura Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acura Pharmaceuticals (ACUR) FAQ

The latest other current liabilities for ACUR is $0 as of September 2023. In the prior-year period, the figure was $0. Investors often review this figure alongside Acura Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACUR's other current liabilities moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acura Pharmaceuticals's operating scale or balance-sheet position.

A other current liabilities figure of $0 for ACUR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ACUR's other current liabilities ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.